Home Featured

Featured

Random

PTSF47 – Covid, Ketamine, and Human Rights

PT397 – Vital Psychedelic Conversations

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California

Changa vs. DMT: What You Need to Know

Psychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree;...

Tolerance, Tachyphylaxis, and Psychedelic Drug Action

Ketamine-Assisted Therapy at Work? The Future of Employee Benefits

Natural Medicine Advisory Bulletin #4: September 2023

The Practitioner’s Guide to Psychedelic Integration Therapy

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart

Natural Medicine Advisory Bulletin 10: March 2024

PTSF86 – Ayahuasca, Chronic Pain, and Legal Psilocybin, with Payton Nyquvest...

Psychedelic Integration and Everyday Transformation: Celebrating the Depths of Intentional Living

Buried Treasure: How Does Psilocybin Reduce Compulsivity?

12 3...307 Page 1 of 307

EDITOR PICKS

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

“Changes Are Never Linear”: Joost Breeksema on the Human Side of...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.